Patents by Inventor Joseph A. Sorge

Joseph A. Sorge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9291627
    Abstract: The present invention provides methods, kits and compositions for the detection of an analyte. In the methods of the invention, a binding molecule coupled to a first polymerase is incubated with a modified polynucleotide template to form a copy of the modified polynucleotide template without any modified nucleotides. The unmodified copy is detected in a second amplification/primer extension reaction using a second polymerase that is unable to amplify the modified polynucleotide template. Detection of the unmodified copy is indicative of the presence and/or amount of the analyte in the sample. In place of the binding molecule coupled to a first polymerase, a pair of analyte-specific probes can also be used. The first analyte specific probe comprises a first binding moiety and a first portion of a first polymerase and the second analyte specific probe comprises a second binding moiety and a second portion of the first polymerase.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: March 22, 2016
    Assignee: Agilent Technologies Inc.
    Inventors: Alexander Belyaev, Craig Monell, Joseph Sorge
  • Patent number: 9181534
    Abstract: The subject invention relates to compositions comprising an enzyme mixture which comprises a first enzyme and a second enzyme, where the first enzyme comprises a DNA polymerization activity and the second enzyme comprises an 5?-3? exonuclease activity and a reduced DNA polymerization activity. The invention also relates to the above compositions in kit format and methods for high fidelity DNA synthesis using the subject compositions of the invention.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: November 10, 2015
    Assignee: Agilent Technologies Inc.
    Inventors: Holly Hogrefe, Michael Borns, Joseph A. Sorge
  • Patent number: 8772006
    Abstract: The invention features a novel isolated Family B DNA polymerase, a Thermococcus polymerase JDF-3, and mutant recombinant forms thereof. Mutant polymerases of the invention are deficient in 3? to 5? exonuclease activity and/or exhibit reduced discrimination against non-conventional nucleotides relative to the wild-type form of the polymerase.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: July 8, 2014
    Assignee: Agilent Technologies, Inc.
    Inventors: Joseph A. Sorge, Connie Jo Hansen, Holly Hogrefe
  • Publication number: 20140024027
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Application
    Filed: January 17, 2013
    Publication date: January 23, 2014
    Applicant: CATALYST ASSETS LLC
    Inventor: Joseph A. Sorge
  • Publication number: 20130183345
    Abstract: Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 18, 2013
    Applicants: CATALYST ASSETS, LLC
    Inventors: Lars Dyrskj√łt Andersen, Torben Falck Orntoft, Joseph A. Sorge, Alexey Novoradovsky
  • Publication number: 20130122504
    Abstract: Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.
    Type: Application
    Filed: December 12, 2011
    Publication date: May 16, 2013
    Inventors: Lars Dyrskjot Andersen, Torben Falck Orntoft, Joseph A. Sorge, Alexey Novoradovsky
  • Patent number: 8383343
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: February 26, 2013
    Assignee: Catalyst Assets LLC
    Inventor: Joseph A. Sorge
  • Patent number: 8338107
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: December 25, 2012
    Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLC
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Patent number: 8314220
    Abstract: The present invention provides methods, nucleic acids, compositions, and kits for detecting microRNA (miRNA) in samples. The methods comprise designing mRNA-specific primers, adding a polyA tail to the miRNA, and using reverse transcription and amplification to detect the miRNA. The nucleic acids, compositions, and kits typically comprise some or all of the components necessary to practice the methods of the invention.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: November 20, 2012
    Assignee: Agilent Technologies, Inc.
    Inventors: Rebecca L. Mullinax, Joseph A. Sorge
  • Patent number: 8283148
    Abstract: The invention relates to the generation and characterization of Archaeal DNA polymerase mutants with deficient 3?-5? exonuclease activity and reduced base analog detection activity. The invention further provides for Archaeal DNA polymerase mutants with deficient 3?-5? exonuclease activity and reduced base analog detection activity containing additional mutations that modulate other DNA polymerase activities including DNA polymerization or reverse transcriptase activity. The invention also discloses methods and applications of DNA polymerases with deficient 3?-5? exonuclease activity and reduced base analog detection activity.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: October 9, 2012
    Assignee: Agilent Technologies, Inc.
    Inventors: Joseph A. Sorge, Reinhold Dietrich Mueller, Gothami Padmabandu, Nick Roelofs, Holly H. Hogrefe
  • Patent number: 8268605
    Abstract: The invention features a novel isolated Family B DNA polymerase, a Thermococcus polymerase JDF-3, and mutant recombinant forms thereof. Mutant polymerases of the invention are deficient in 3? to 5? exonuclease activity and/or exhibit reduced discrimination against non-conventional nucleotides relative to the wild-type form of the polymerase.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: September 18, 2012
    Assignee: Agilent Technologies, Inc.
    Inventors: Joseph A. Sorge, Connie Jo Hansen, Holly Hogrefe
  • Patent number: 8263338
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: September 11, 2012
    Assignee: Catalyst Assets LLC
    Inventor: Joseph A. Sorge
  • Patent number: 7932070
    Abstract: The subject invention relates to compositions comprising an enzyme mixture which comprises a first enzyme and a second enzyme, where the first enzyme comprises a DNA polymerization activity and the second enzyme comprises an 3?-5? exonuclease activity and a reduced DNA polymerization activity. The invention also relates to the above compositions in kit format and methods for high fidelity DNA synthesis using the subject compositions of the invention.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: April 26, 2011
    Assignee: Agilent Technologies, Inc.
    Inventors: Holly Hogrefe, Michael Borns, Joseph A. Sorge
  • Patent number: 7858359
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: December 28, 2010
    Assignees: Stratagene, Medical Research Council
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner
  • Patent number: 7846661
    Abstract: The present invention is directed to methods of generating a signal indicative of the presence of said target nucleic acid sequence in a sample, comprising, incubating a sample comprising a an amplified target nucleic acid and a nucleic acid polymerase which substantially lacks 5? to 3? exonuclease activity, adding a thermostable fen nuclease consisting of 5? to 3? exonuclease and/or endonuclease activity so as to cleave a cleavage structure and generate a signal.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: December 7, 2010
    Assignee: Hologic, Inc.
    Inventor: Joseph A. Sorge
  • Patent number: 7838225
    Abstract: The invention relates to and methods for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions and methods include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: November 23, 2010
    Assignee: Hologic, Inc.
    Inventor: Joseph A. Sorge
  • Patent number: 7824859
    Abstract: The invention relates to compositions and methods for generating a signal indicative of the presence of a target nucleic acid in a sample, where the compositions and methods include an RNA polymerase, a FEN nuclease, and a probe.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: November 2, 2010
    Assignee: CYTYC Corporation
    Inventor: Joseph A. Sorge
  • Patent number: 7807365
    Abstract: The invention relates to compositions and methods of generating a signal indicative of the presence of a target nucleic acid in a sample, where the method includes forming a cleavage structure by incubating a sample comprising a target nucleic acid with a probe. The invention also includes the steps of cleaving the cleavage structure with a nuclease to release a nucleic acid fragment to generate a signal, wherein generation of the signal is indicative of the presence of a target nucleic acid in a sample.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: October 5, 2010
    Assignee: Hologic, Inc.
    Inventor: Joseph A. Sorge
  • Publication number: 20100248246
    Abstract: The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample.
    Type: Application
    Filed: March 29, 2010
    Publication date: September 30, 2010
    Applicant: CATALYST ASSETS LLC
    Inventors: Joseph A. Sorge, Ronald W. Davis
  • Patent number: 7794935
    Abstract: The invention relates to compositions for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions include a reverse transcriptase, a nuclease, an upstream primer and downstream probe.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: September 14, 2010
    Assignee: Hologic, Inc.
    Inventor: Joseph A. Sorge